Cairns H S, Dawnay A, Woolfson R G, Unwin R J
Division of Nephrology, UCL Medical School, London, UK.
Exp Nephrol. 1994 Jul-Aug;2(4):257-8.
Tamm Horsfall glycoprotein (THG) is a major constituent of renal tubular casts including the light chain casts of myeloma. Animal studies suggest that the anti-inflammatory agent colchicine reduces urinary THG excretion and prevents light chain cast formation. Six normal male subjects were given therapeutic doses of colchicine (0.5 mg twice daily for 6 days) and excretion of THG, albumin, creatinine and N-acetyl glucosaminidase (NAG) was determined. Colchicine therapy had no effect on the urinary excretion of THG, albumin or NAG or on renal function as assessed by creatinine clearance. This suggests that colchicine will not be a useful therapeutic adjunct to the treatment of light-chain nephropathy.
Tamm-Horsfall糖蛋白（THG）是肾小管管型的主要成分，包括骨髓瘤的轻链管型。动物研究表明，抗炎药秋水仙碱可减少尿THG排泄并防止轻链管型形成。对6名正常男性受试者给予治疗剂量的秋水仙碱（每日两次，每次0.5毫克，共6天），并测定THG、白蛋白、肌酐和N-乙酰氨基葡萄糖苷酶（NAG）的排泄情况。秋水仙碱治疗对THG、白蛋白或NAG的尿排泄以及通过肌酐清除率评估的肾功能均无影响。这表明秋水仙碱不会成为治疗轻链肾病的有用辅助治疗药物。
